NCT02192775 · OUTCOME

The Effectiveness of MV-NIS Therapy as Measured by the International Myeloma Working Group (IMWG) Guidelines

UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus · Source last updated 2020-10-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: 1 year

What was measured

The primary objective of this study is to assess the effectiveness of MV-NIS therapy for people with relapsed/refractory myeloma when given with cyclophosphamide

Analysis population: Only two subjects were enrolled. Both passed away while enrolled. No data were collected.

Groups in this outcome

MV-NIS + Cyclophosphamide

MV-NIS: one dose in conjunction with a 4 day course intravenously

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
MV-NIS + Cyclophosphamide	0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

counts
group Id
OG000
value
0
units
Participants

description

The primary objective of this study is to assess the effectiveness of MV-NIS therapy for people with relapsed/refractory myeloma when given with cyclophosphamide

groups

description
MV-NIS: one dose in conjunction with a 4 day course intravenously
id
OG000
title
MV-NIS + Cyclophosphamide

population Description

Only two subjects were enrolled. Both passed away while enrolled. No data were collected.

reporting Status

POSTED

time Frame

1 year

title

The Effectiveness of MV-NIS Therapy as Measured by the International Myeloma Working Group (IMWG) Guidelines

type

PRIMARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice